HOME >> BIOLOGY >> NEWS
Braunschweig Prize 2003 for Molecular Cancer Therapy

Ten years ago the medic began working with the compound Imatinib that works against chronic myeloid leukemia (CML) and is commercially known as Glivec. Glivec blocks a protein that triggers the uncontrolled reproduction of white blood cells. "The name Brian Druker has become synonymous with a breakthrough in cancer therapy," said Braunschweig's mayor and chairman of the jury, Dr. Gert Hoffmann on the 8th of July after the vote of the council. Every year approximately 1700 people in Germany fall ill with CML. Some of the first patients to be treated with Glivec came from Germany.

Druker received his M.D. in 1981 from the University of California in San Diego. At Harvard Medical School he specialized in cancer research. Since 1993, Druker leads leukemia research at the Oregon Health & Science University Cancer Institute in Portland (USA). He is Investigator of the Howard Hughes Medical Institute and JELDWEN Chair of Leukemia Research. On the 27th of October he will accept the Braunschweig prize at the congress "Life in Tomorrow's World."

The American cancer researcher Prof. Dr. Brian Druker will be recognised for his research into molecular cancer ther-apy with the 50,000 Euro Braunschweig Prize, the highest research prize from a German city.

The 48-year-old medic is regarded as the pathfinder of the first tailor-made pill for the treatment of cancer. Ten years ago, in collaboration with the pharmaceutical company No-vartis, he identified the compound Imatinib, which in the meantime has become commercially available as Glivec. In contrast to chemotherapy that attacks both healthy and diseased cells, Imatinib targets a single protein that trig-gers the uncontrolled growth of white blood cells in chronic myeloid leukemia (CML). Every year approximately 1700 people in Germany fall ill with this blood cancer.

A recent study involving 1006 patients, comparing Glivec to standard therapy for CML, led by Druker, had to be stopped early because
'"/>

Contact: Jrgen Sperber
juergen.sperber@braunschweig.de
49-531-470-2212
Stadtverwaltung Braunschweig
8-Jul-2003


Page: 1 2

Related biology news :

1. Half-million dollar landmark achieved for the Methuselah Mouse Prize
2. Winner of 2004 EMBO Science Writing Prize announced
3. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
4. Stuart Lipton honored with Jung Prize for Medicine
5. 2004 Max Planck Research Prize for Martin Vingron and Eugene W. Myers
6. Scripps research scientist wins 2004 Koch Prize
7. Ohio State wetlands professor wins prestigious Water Prize
8. Tony Hunter and Raymond N. DuBois awarded Landon-AACR Prizes for Cancer Research
9. Leibniz Prizewinners 2004
10. Roderick MacKinnon wins 2003 Nobel Prize in Chemistry
11. Illinois professor wins Nobel Prize

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/24/2017)...  It sounds simple and harmless—an electronic sensor ... signs and alerts parents on their smart phones ... drops. But pediatric experts argue that such devices ... evidence of medical benefits, especially to healthy babies. ... parents of healthy babies, promising peace of mind ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 /PRNewswire/ ... titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the ... at a CAGR of 9.6% from 2016 to 2022. In 2015, ... to high-level security for both public and private sectors. ... ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... A study recently ... in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, when ... studies. , Jake Lubinski, president of AxioMed, commented on the recent publication, ...
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... Feb. 24, 2017  Driven by consumers, preference ... now the fastest growing categories, finds the recently ... in Personal Care: Multi-regional Market Analysis and Opportunities ... consulting firm Kline. "Biotechnology actives are ... them more effective for skin and hair care ...
Breaking Biology Technology:
Cached News: